ISRG — Intuitive Surgical
A surgical franchise this good can still be too expensive for the return on offer.
Founded in 1995, Intuitive built da Vinci into a robotic surgery ecosystem combining installed systems, surgeon training, recurring instruments and accessories, and long-term service. The franchise remains exceptionally strong, but paying around 48x trailing GAAP EPS still leaves an important question: how much of that quality can I buy at a return worth earning?
I love the business more than the stock at $415. That’s the tension.
Why I care about this one
At June 30, 2026, Intuitive had about 11,710 installed da Vinci systems, 12% more than the prior year, and utilization increased roughly 3%. Together, that explains approximately 15% procedure growth. Ion grew procedures 36% with 1,096 installed systems. New da Vinci 5 hardware matters because of what those systems can earn over their useful lives, not simply because 246 were placed in Q2.
Intuitive was founded in 1995, received U.S. clearance in 2000, acquired Computer Motion in 2003, and built the Xi, SP, Ion and da Vinci 5 platforms over subsequent decades. The switching costs sit in training, workflow, instrument economics and long-lived hospital programs.
2025 revenue was $10.065B and GAAP diluted EPS $7.87. Reconstructing FY2025 plus H1 2026 minus H1 2025 produces roughly $11.034B trailing revenue and $8.72 trailing EPS. At $415.47, that is 47.6x trailing GAAP EPS.
For FY2026, I assume $11.650B revenue, 28.5% attributable net margin and 358M diluted shares, which generates roughly $9.27 EPS. That’s approximately 44.8x the estimated FY2026 earnings, not 41.5x just because an older framework used $10.
The full October 8, 2026 Research Note works through the history, audited financials, last-twelve-month reconstruction, every line of the FY2031 operating model, competition and downside sensitivities.
The installed-base flywheel matters: roughly 11,710 da Vinci systems at June 2026, up 12%, paired with about 3% higher utilization, helps explain roughly 15% procedure growth. In 2025, 84% of reported revenue qualified as recurring under the company's definition. Da Vinci 5 and Ion can expand the ecosystem, but competitive FDA clearances for Hugo and OTTAVA, hospital budgets, lease accounting, stock compensation and third-party instrument competition all deserve an explicit underwriting discount.
Q2 2026 / FY2025
Primary sources: 2025 Form 10-K ↗ · Q2 2026 Form 10-Q ↗ · Q2 2026 results ↗
Q2 2026 revenue rose 19%, da Vinci procedures 15% and Ion procedures 36%; the da Vinci installed base reached 11,710. The FY2031 operating Base assumes revenue grows 14% annually from a modeled $11.65B FY2026 base, with a 33.5% operating margin and 36x terminal P/E. At $415.47, this implies roughly a 9% annualized return; the entry remains above the return-based starter threshold.
Da Vinci 5's productive installed base grows with stable instrument revenue per procedure; utilization strengthens, Ion reaches meaningful scale, hospital program retention stays high despite new competitors, and GAAP operating margins improve without sacrificing R&D.
Medtronic Hugo or J&J OTTAVA capture meaningful new programs, third-party instrument remanufacturing reduces recurring economics, surgeon outcomes or reimbursement fail to justify cost, international procurement slows, recurring revenue per procedure softens, or diluted shares stop shrinking despite heavy buybacks.
What gets this into the portfolio
Full bottom-up FY2031 underwriting of da Vinci and Ion economics. ISRG passes the quality test (Compounder 9.0/10), but the ~$651 Base offers only about 9% annualized from the $415.47 user-supplied screen price. No capital allocated; about $360 needed for a 12% modeled return.
Valuation & scenario math
Medtronic’s Hugo received U.S. clearance for urological surgery in December 2025. J&J’s OTTAVA won FDA authorization for multiple upper-abdominal general surgeries in July 2026. Neither has Intuitive’s installed-base economics yet. I also don’t want to assume a 36x multiple survives if hospitals get more viable alternatives or the recurring economics per procedure soften.
At $415.47, ISRG trades around 47.6x reconstructed trailing GAAP EPS of $8.72, or 44.8x my FY2026 $9.27 GAAP EPS estimate. A bottom-up FY2031 Base of $22.43B revenue, 33.5% operating margin, $6.31B attributable net income and 349M diluted shares gives $18.08 EPS. At 36x, that is about $651, or 9.0% annualized over 5.23 years. At 32x, the same operating outcome is about $579 and 6.5% annualized. My 12% starter hurdle implies an entry near $360, not $415.
“My current view” is the output of my dated valuation framework, not a magical buy instruction. A BUY still has to beat the expected return of what I already own and the index before it gets actual money.
FY2031 base share value / required five-year-plus annualized return
| Band | Buy price | Model base center | Annualized return at entry |
|---|---|---|---|
| Starter | $360 | $651 | +12.0% |
| Normal | $313 | $651 | +15.0% |
| Aggressive | $274 | $651 | +18.0% |
The zone label uses the live quote when available; the model itself is anchored to the Oct 8, 2026 reference close at $415. The 48x/42x/36x multiples on a $10 normalized EPS proxy looked investable at $415. The independent forward-return model puts the first 12% entry closer to $360. These thresholds move if earnings assumptions change.
The full fiscal 2026–2031 model builds revenue, gross margin, SG&A, R&D, pretax income, 18% tax, noncontrolling interest and diluted shares from reported FY2025/H1 2026 data. Implied EPS growth rates below are calculated from that operating bridge, not the starting assumptions. The dated Research Note contains every line.
| Normalized EPS today | $9.27 |
| Annual EPS growth | 14% |
| EPS by Dec 31, 2031 | ~$18.08 |
| Terminal P/E | 36x |
| Implied base price | ~$651/share |
The base case is basically ~$18.08 of Dec 31, 2031 EPS at 36x, or about $651/share. Same math, just without making the reader decode equation soup.
| Case | What has to be true | Target range | Total return* | Annualized return* |
|---|---|---|---|---|
| Bear | 4% annual EPS growth · 26x terminal P/E. 8% revenue CAGR from 2026, 66.5% gross margin, 29% operating margin, 18% tax, +0.5% annual diluted share growth; competitive and valuation pressure. | $276–$317 center ~$296 | -28.6% | -6.2% |
| Base | 14% annual EPS growth · 36x terminal P/E. 14% revenue CAGR, 69% gross margin, 33.5% operating margin, 18% tax, −0.5% annual diluted share change; continued da Vinci and Ion adoption. | $605–$696 center ~$651 | +56.7% | +9.0% |
| Bull | 20% annual EPS growth · 42x terminal P/E. 18% revenue CAGR, 71% gross margin, 36% operating margin, 18% tax, −1% share count annually; durable category leadership. | $923–$1,062 center ~$993 | +138.9% | +18.1% |
*The static returns use the dated reference price. The annualized figure on the live page also refreshes from the current quote. For shorter model horizons, annualizing can make the number look ridiculous, so I care about total return and the underlying milestones at least as much.
Capital allocation
Most of the money is going exactly where I would want it to go.
R&D, installed-base expansion and manufacturing capacity directly reinforce the moat, and the balance sheet can fund all of it without financial engineering. Repurchases add some alignment without becoming the whole capital-allocation story.
Stage-relative, not some objective rating-agency grade. The number is there to force the judgment into the open. See the rubric →
What management is actually doing with the cash
The obvious place for money here is R&D, manufacturing capacity and more productive systems in hospitals. Each good placement can create years of recurring economics. I would much rather see Intuitive keep widening the technical and clinical lead than decide the balance sheet needs some unrelated giant acquisition.
What earns another dollar from me
The forward-return entry prices from the same $651 Base are approximately $360 for 12% annualized, $313 for 15%, and $274 for 18%. Those are opportunity-cost hurdles, not predictions.
Intuitive scores 9.0/10 on capital allocation: strong reinvestment, excellent balance sheet, coherent strategic focus. The main deductions are stock compensation and the capital intensity/discipline of repurchases and system leasing.
I’m Ready at the right price, not an owner. At $415, the modeled return loses to alternatives I can already buy. Around $360 with the thesis intact, a small starter becomes a serious conversation.
What can break this
The FY2031 Base starts with $11.65B of FY2026 revenue and assumes 14% annual revenue growth, 69% gross margin, 23% SG&A, 12.5% R&D, 18% tax and 0.5% annual share shrink. That gets me to approximately $22.43B sales, $6.31B attributable net income and $18.08 EPS.
At 36x terminal P/E, that’s about $651 per share, or 9.0% annualized from $415 over 5.23 years. At a less generous 32x, the same earnings are worth $579, or 6.5% annualized.
The 2031 Bear / Base / Bull endpoints are roughly $296 / $651 / $993. I am not using $603.88 as a price target just because the stock was there in January.